When people talk about the NHS crisis in trans youth care, they usually mean waiting lists: thousands of young people waiting years to be seen. That is real, and it is serious. But there is something happening that is harder to name and, I think, more immediately damaging. Young people who are already on treatment, who have been on blockers or hormones for months or years, are being told that treatment is stopping. Not because their care has been reviewed and found wanting. Because the service is closing, the prescription is expiring, and there is nowhere left to go. That is not a waiting list problem, it is forced detransition, and it is an active policy harm.
What is actually happening to young trans people in NHS care?
The Tavistock and Portman NHS Foundation Trust's Gender Identity Development Service (GIDS) was closed following the Cass Review, and regional services are in the early stages of replacing it. Those regional services are not yet running at anything like the capacity needed. The result is a gap, and young people fall into it.
Some of those young people were already on puberty blockers. Some were already on gender-affirming hormones. They had been assessed, referred, prescribed, and were progressing through a pathway that was working for them. Then the service closed. Referrals to bridging care, to private providers, or to adult services have not been straightforward for most of them. Many have simply had their medication stop.
This is not the same as a long wait before treatment begins. A young person who has never started hormones is in a painful, dysphoric position, but their body has not yet changed in the direction their gender needs. A young person who has been on oestrogen or testosterone, whose body has begun to change accordingly, and who then loses access to that medication, faces something categorically different: their body reverting, or continuing to develop in the wrong direction, because the prescription ran out and the NHS has no mechanism to renew it.
Why calling this a "waiting list crisis" hides what is actually wrong
The language of waiting lists carries an implicit reassurance: the care exists, the question is just how long until you reach it. Forced detransition does not carry that reassurance, because the care is not waiting at the end of a queue. For the young people I am describing, there is no queue. There is a void.
The political framing around the Cass Review was built on the idea of caution: slow down, be careful, do more research, protect children from irreversible interventions. I understand why that language has traction with people who have not looked closely at the evidence. But the young people whose treatment has been interrupted are not being protected from irreversible interventions. They are being subjected to one. Stopping hormones mid-pathway is an intervention. The body changes that follow are not neutral. The psychological consequences of losing treatment that was working are not neutral. Calling the inaction safe is one of the most persistent and damaging distortions in this whole debate.
What does forced detransition actually mean for a young person?
People tell me, and the research reflects this, that losing access to gender-affirming care mid-pathway is not experienced as a pause. It is experienced as a collapse. The dysphoria that the treatment was managing does not simply wait patiently. It returns, often with force. For a young person who had started to feel at home in their body, that return is not abstract. It is visible, felt, and relentless.
For those on testosterone, menstruation may return. For those on oestrogen, masculinisation that had slowed may resume. For all of them, the social reality of their life, school, friends, family, the face in the mirror, is thrown into a new kind of conflict. The harm from that is measurable. The research on the mental health consequences of interrupted gender-affirming care, particularly for young people, is not ambiguous.
And beyond the physical: what does it tell a young person that the NHS started their care, allowed them to begin changing, and then withdrew the medication and left? It tells them that the state does not believe their gender is real enough to maintain. That is a message with consequences that outlast the prescription.
How did we get here, and who made this happen?
The Cass Review is widely discredited internationally. Gender experts, clinicians, and researchers have published detailed rebuttals of its methodology and its conclusions. Its citation behaviour drew heavily on SEGM-linked work, a network that functions as a gatekeeping advocacy operation rather than independent evidence-based research. The review nonetheless became the basis for UK policy, and the policy consequences have been severe.
The ban on puberty blockers being supplied on private prescription to trans young people in the UK was a direct policy response to the review. NHS prescriptions became almost impossible to obtain not because the clinical case against them is strong, it is not, but because the services that prescribe them were dismantled. What remained was not a reformed pathway delivering better-evidenced care. What remained was largely nothing.
The young people caught in this gap did not make a policy choice. They were receiving care, within a system that had assessed and prescribed for them, and the system withdrew. The responsibility for that lies with the policy decisions that closed GIDS without an adequate, functioning replacement, and with the legal restrictions that closed private routes at the same time. Both doors shut simultaneously. For the young people already on treatment, that meant forced detransition.
What the international guidelines say
WPATH Standards of Care 8 and the Endocrine Society guidelines both recognise that continuity of care is not a luxury in gender-affirming treatment: it is a clinical requirement. Interrupting a hormonal pathway without clinical reason is not a neutral act. The guidelines do not support removal of treatment as a default response to service reorganisation.
Puberty blockers have been used for decades in paediatric endocrinology, including for precocious puberty, long before they were used in gender care. Their safety profile is understood. The framing of them as uniquely dangerous or experimental is not a clinical finding; it is a political one, and it has been used to justify a policy that has caused real, documented harm to real young people.
What needs to change
The regional services replacing GIDS need to be adequately resourced and need to begin seeing young people at the volume required, which means not the volume of an NHS service operating with years of political headwind, but the volume that the actual demand requires. That means funding, staffing, and a political environment that treats these young people as patients rather than as a debate.
Young people already on treatment when GIDS closed need to have had their care bridged, not abandoned. Where that has not happened, the NHS has a responsibility to those individuals that has not been discharged.
The ban on private prescriptions for puberty blockers has removed the safety valve that some families could afford and chose. Whatever one thinks of private medicine, removing a legal option without providing a public one is not protection. It is abandonment with a policy justification attached.
And the language needs to change. When a young person loses their medication because the service that prescribed it has been closed, that is not a waiting list. It is forced detransition. Naming it accurately is not inflammatory. It is the minimum required to understand what is happening and why it has to stop.
Comments